Apellis Slashes Costs To Focus On Troubled Syfovre Launch

Cuts To Jobs And Pipeline

The blockbuster-tipped eye therapy Syfovre has hit safety doubts and Apellis is streamlining to give more support to the drug’s global launch.

Apellis
• Source: Apellis

Apellis Pharmaceuticals has slashed its headcount by a quarter and culled its pipeline to save $300m, which will be put towards supporting the ongoing launch of its potential blockbuster eye therapy, Syfovre.

Syfovre (pegcetacoplan injection) became the first ever US Food and Drug Administration approved treatment for geographic atrophy (GA) in February...

More from Strategy

More from Business